Systemic Therapy for IMDC Poor-Risk Metastatic RCC with Bone Metastasis

First-Line Systemic Therapy Selection

The National Comprehensive Cancer Network recommends cabozantinib-nivolumab as the preferred regimen for IMDC poor-risk disease with bone involvement, showing improved PFS (HR 0.34; 95% CI 0.22-0.55) and OS (HR 0.54; 95% CI 0.32-0.92) compared to sunitinib in the bone metastases subgroup 1
The American Society of Clinical Oncology suggests lenvatinib-pembrolizumab as an alternative first-line option, demonstrating significant OS advantage (HR 0.66, 95% CI 0.49-0.88, P=0.005) with median OS not reached versus sunitinib 2
The European Society for Medical Oncology recommends ipilimumab-nivolumab for IMDC intermediate- and poor-risk disease, as a dual checkpoint inhibitor approach is appropriate for poor-risk patients 3, 2, 4

The American College of Radiology recommends initiating either zoledronic acid or denosumab immediately alongside systemic therapy to prevent skeletal-related events (SREs), as these agents delay time to first SRE and reduce annual incidence of SREs in metastatic RCC patients with bone involvement 1, 4
The National Comprehensive Cancer Network suggests bone-directed radiation therapy should be administered for symptomatic bone metastases, which this patient has given the pathological fracture requiring surgical fixation 4, 5
The European Association of Urology recommends stereotactic body radiotherapy (SBRT) as the preferred modality when feasible, showing 1-year local control of 90% with only 1% significant toxicity in RCC oligometastases 6, 1

The American Urological Association advises against immediate cytoreductive nephrectomy in IMDC poor-risk patients, as the CARMENA trial demonstrated that sunitinib alone had longer median OS (18.4 vs 13.9 months) compared to immediate cytoreductive nephrectomy followed by sunitinib in intermediate- and poor-risk patients 6, 1
The Society of Surgical Oncology recommends ensuring adequate performance status before initiating combination therapy, and the patient's post-operative status from humerus plating should be optimized before starting systemic therapy 3, 7, 1

The National Comprehensive Cancer Network suggests continuing systemic therapy until disease progression or unacceptable toxicity, and treatment beyond progression may be permitted if the patient is clinically stable and deriving clinical benefit 4, 5